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Use of surfactant in neonatal intensive care units
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which lines the alveoli and smallest bronchioles.
Surfactant reduces surface tension throughout the
lung, thereby contributing to its general compliance.
It is also important because it stabilizes the alveoli.
Surfactant is formed relatively late in fetal life; thus
premature infants born without an adequate amount
of it experience respiratory distress and may die.2
Endogenous surfactant, normally produced by type
II alveolar epithelial cells within the lung, is primarily
responsible for the prevention or reduction of alveolar
collapse due to an increase in surface tension within the
alveoli. Because the process of surfactant production
takes place relatively late in fetal life (from 22 to 24 weeks
gestation throughout 32 weeks gestation), infants born
prematurely are at risk for surfactant deficiency. This
deficiency results in the development of RDS, also known
as hyaline membrane disease (HMD).3
Types of surfactant
Pulmonary surfactant is a complex mixture of lipids
and specific apoproteins, 80% phospholipids, 8%
neutral lipids, and 10-12% proteins. The phospholipid
S
urfactant is currently an important therapy
for newborns in neonatal intensive care units
(NICUs) with respiratory problems,
specifically respiratory distress syndrome
(RDS). Surfactant was initially used in 1959, after it
was recognized for maintaining lung inflation at low
transpulmonary pressures. Avery and Mead in Jobe1
reported that saline extracts from the lungs of
preterm infants with RDS lacked the low surface
tension characteristics of pulmonary surfactant.
Subsequently, in 1980, clinical potential of surfactant
therapy for RDS was demonstrated by Fujiwara et al,
reported in Jobe,1 in the use of surfactant prepared
from an organic solvent extracted from bovine lung
(Surfactant TA). Small randomized controlled trials
(RCTs) in 1985, which tested surfactants prepared
from bovine alveolar-lavage or human amniotic fluid,
demonstrated significant decrease in pneumothorax
and death rates. Subsequent multi-center trials
demonstrated decreased death rates and
complications of RDS; although still investigational,
its use begun in 1989. A synthetic surfactant was
approved for the treatment of the syndrome in the
United States in 1990, and an animal surfactant was
approved in 1991. These surfactants represent a new
class of drug developed specifically for preterm
infants.1
Characteristics of surfactant
Surfactant is a complex substance containing
phospholipids and a number of apoproteins. This
essential fluid is produced by the Type II alveolar cells
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component consists of 60% saturated
phosphatidylcholine (PC), 20% unsaturated PC and
anionic phospholipids, phosphatidylglycerol (PG), and
phosphatidylinosotol. The main active component is
dipalmityl phosphotidylcholine (DPPC) which is
responsible for reducing surface tension and
maintaining alveolar stability, both animal and
artificial surfactants are available in the market. The
former, derived from bovine and porcine lungs,
contains surfactant proteins B and C. It is more
effective than artificial surfactant which lacks these
surfactant proteins.4 The Canadian Pediatrics Society
recommends the use of natural surfactants in
preference to any synthetic ones available.5
Pharmacokinetics of surfactant
Infants with RDS have pools of surfactant on the order
of 5 mg per kilogram, whereas in newborn animals the
pool is about 100 mg per kilogram. The usual dose of
100 mg per kilogram approximates the amount of
surfactant in the air spaces of term newborn animals.
However, much of this surfactant rapidly becomes lung
associated and cannot be recovered by alveolar lavage.1
Indications for the use of surfactant
Neonatal surfactant deficiency states, especially HMD
in premature infants, require surfactant treatment.3,6
Surfactant is also used in neonatal lung injury not
related to prematurity, such as congenital
diaphragmatic hernia (before and after surgical repair)
and meconium aspiration syndrome.4,5 Other
indications requiring surfactant for therapy are lung
injury in neonates, infants, and children (inhalation
syndrome, bacterial pneumonia, bronchiolitis), and
adult respiratory distress syndrome (ARDS) which
includes those of sepsis-induced, trauma, hypoxic
respiratory failure, oncohematologic cases in children
and adolescents.4
Risks of exogenous surfactant therapy
The short-term risks of surfactant replacement
therapy, for example, are bradycardia, hypoxemia, and
increase in pulmonary hemorrhage. Bradycardia,
hypoxemia, and blockage of the endotracheal tube
may occur during instillation. There is also a chance
of increase in pulmonary hemorrhage following
surfactant treatment. However, mortality ascribed to
pulmonary hemorrhage is not increased and overall
mortality is lower after surfactant therapy. The relative
risk (RR) for pulmonary hemorrhage following
surfactant treatment has been reported at
approximately 1.47 (95% CI 1.05 to 2.07) in trials
but, unfortunately, many of the RCTs on surfactant
replacement have not reported this outcome, nor have
the data from autopsy studies clearly defined the
magnitude of this (evidence level 1a).5
As of yet, there is no evidence of immunological
change which may influence clinical concern. Babies
with RDS have detectable circulating immune com-
plexes directed towards surfactant proteins, but these
do not appear to be more frequent in babies are treated
with surfactants.4,5
FIGURE 1. ALVEOLI WITH AND WITHOUT SURFACTANT2
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Timing of surfactant treatment
Initially, surfactant was administered 6 to 24 hours
after birth when diagnosis of severe RDS could be
made accurately. In contrast, delivery-room
treatment was considered to be optimal if given
before the infant breathed or received positive-
pressure ventilation (PPV). This delivery room
strategy was based on information from surfactant
treatment of preterm animals demonstrating airway
epithelial damage with minimal ventilation of the
surfactant-deficient lung. The  two treatment
strategies have been compared in three independent
trials using different surfactants. The efficacy of the
two strategies was similar in one trial that included
55 infants who were treated in the delivery room and
50 infants who were treated at a mean age of 3.7
hours.1
Retreatment should be considered when there
is a persistent or recurrent oxygen requirement of 30%
or more and it may be given as early as 2 hours after
the initial dose or, more commonly, 4-6 hours after
the initial dose.5
Clinical Implications
Circulatory Effects
A number of investigators have looked into the
cardiovascular effects of surfactant therapy. It can
be expected that surfactant will improve lung
compliance which leads to a decrease in pulmonary
vascular resistance and an increased pulmonary
blood flow. The clinical observation of patent
ductus arteriosus (PDA) following surfactant
treatment was thought to be due to the drop in
pulmonary vascular resistance (PVR). Although
there is a demonstrable decrease in PVR and an
increase in pulmonary artery pressure (PAP) and
pulmonary blood flow and consequent development
of PDA, there is decreasing incidence of PDA with
better management suggesting surfactant per se is
not the cause for the PDA.6
Increased incidence of PDA following surfac-
tant therapy has been widely reported. A meta-analy-
sis of 6117 infants from 28 studies showed no gen-
eral increase in PDA after treatment.6
Cerebral circulation
Although some authors have reported a decrease in
cerebral blood flow volume (CBFV), others showed
an increased CBFV; however, there are no significant
changes that occurred with surfactant therapy. Porcine
surfactant decreases mean arterial blood pressure
(MABP) by inducing vasodilation. The effect is dose
dependant. This vasodilatation is inhibited by nitric
oxide (NO) synthetase by LNAME with Curosurf
MABP and left ventricular cardiac output increased
about 29 percent; other studies did not show
consistent results.6
Pulmonary functions
Pulmonary functions have been studied in infants
treated with surfactant. In exosurf treated infants,
compliance improved 24 hours after treatment; forced
respiratory capacity (FRC) increased 12 hours after
treatment. Improvement in oxygenation is not
followed by improvement in compliance. The
immediate improvement may be due to improvement
in ventilation perfusion ratio.4,6
 Renal function
The onset of spontaneous diuresis was evaluated in
19 infants with HMD, in a double-blind controlled
study, 12 with surfactant and 7 as control. There was
no difference in the time of onset for diuresis output
of >80% intake. Glomerular filtration rate (GFR) was
similar in the surfactant group and control group
during the first 3 days of life. Ventilator status
improved soon after surfactant therapy. Data suggested
ventilatory status improvement was not due to
diuresis. Other factors are thought to be responsible.6
Treatment response
Uniform improvement in oxygenation has been found
after surfactant treatment. Some response may be poor
due to existing acidosis from severe hypoxia or
myocardial failure. In a small percentage, poor response
may result from the presence of PDA. Infants with
cyanotic congenital heart disease will show no response.
An initial good response followed by reversal may result
from inappropriate ventilatory management following
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surfactant therapy (e.g. not changing peak pressure with
subsequent development of pneumothorax).8
Role of surfactant in host defenses
Surfactant proteins A and D are being increasingly
identified as important factors in host defense of lung.
Surfactant protein A (SPA), binds and opsonizes bacteria,
including group B streptococcus, pseudomonas, and
pneumococcus. It agglutinates herpes and influenza virus,
and attaches to lipoprotein synthesis (LPS) endotoxin.
SPA deficient mice are susceptible to Group B
Streptococcus (GBS) infection. SPA concentrations are
low in lavage fluid from premature infants. It decreases
by infection from RSV, bacteria, LPS and tumor necrosis
factor-X (TNFX). SPA also activates macrophages and
polymorphonucleocytes (PMNs), enhances destruction
of bacteria. Surfactant protein D synthesized by
bronchiolar, tracheal-bronchial and alveolar epithelial
cells. It binds E.coli, Salmonella, Klebsiella, increasing the
uptake and killing of bacteria. It also agglutinates virus,
and binds with LPS. Concentrations in bronchi-alveolar
lavage are low in prematurity. Thus, natural surfactant
plays unknown roles that are very critical for the survival
of immature infants.6
Administration of surfactant
Some points should be considered before surfactant
installation, such as its administration. Direct instillation
manages surfactant directly into the distal end of the
tracheal tube via a premeasured bronchial suction
catheter, or via nebulizer in ventilator gases. Direct
instillation is less efficient and leads to surfactant loss in
the endotracheal tube. The most uniform distribution
of surfactant is by using a nebulizer during a brief period
of manual ventilation (2-3 minutes), with respiratory
physiotherapy and postural drainage. In Indonesia, such
surfactant is not available. Administration of surfactant
in 2-4 divided doses avoids early deterioration of gas
exchange and unwanted vagal reflexes. The airways
should not be suctioned for the first hour after surfactant
administration.
Several studies have demonstrated the benefi-
cial effects of applied positive end expiratory pressure
(PEEP) in improving and sustaining the therapeutic
effects of surfactant. Using a conventional tube has
been suggested in selective bronchial instillation of
surfactant which is presented in one main bronchus
by a bilumen tube or bronchoscope. The advantages
deriving from this method is the delivery of large doses
to distal regions of the lung and the reduction of in-
stilled dose (costs). The disadvantages are connected
with the complexity of procedures and length of treat-
ment.4 To avoid adverse reactions, a sedative or pain
reliever is sometimes needed.
Surfactant replacement therapy
Initial reports of significant improvement in the
clinical course of infants with severe HMD, following
the installation of surfactant, are most encouraging.
Fujiwara, reported in Chernick,7 instilled a liquid
surfactant into the trachea of infants with HMD which
was obtained from tracheal washings of cow lung and
modified to exclude most of the protein (Fujisurf). The
British have used a dry powder insufflation which
consisted of a combination of dipalmitoyl lecithin and
diacylphosphotidylglycerol (7:3 ratio, water/water).
This approach is proven to be a major advance in our
therapy of those infants with HMD whose lungs can
not be matured in utero. Certainly, one might speculate
that replacement therapy will succeed artificial
ventilation as the therapy of choice in the future,
thereby avoiding the serious complications associated
with prolonged ventilation of these tiny infants.7
Horbar et al9 conducted a study in NICUs involv-
ing 114 units which treated 6039 infants of 23-29 weeks
gestation born in 2001. Results of this study revealed
that compared to control hospitals, infants in interven-
tion hospitals were more likely to receive surfactant in
the delivery room [adjusted odds ratio 5.38 (95% CI
2.84 to 10.20)] were less likely to receive the first dose
more than two hours after birth [adjusted odds ratio
0.35 (0.24 to 0.53)], and received the first dose of sur-
factant soon after birth (median of 21 minutes vs 78
minutes, P<0.001). The intervention effect on timing
of surfactant was larger for infants born in the partici-
pating hospitals than for infants transferred to a par-
ticipating hospital after birth. There were no signifi-
cant differences in mortality or pneumothorax. Con-
clusion of this study was a multifaceted intervention
including audit and feedback, evidence reviews, qual-
ity improvement training, and follow-up support which
changed the behavior of health professionals and pro-
moted evidence based practice.9
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Narang et al10 conducted another study on 207
babies with HMD requiring mechanical ventilation
were admitted in NICU. Out of these, 88 babies re-
ceived surfactant. Amongst those who received sur-
factant, 65% received one dose, 25% received two
doses and 10% received three doses. The babies in
both groups had comparable characteristics except for
those delivered by Cesarean Section, which was sig-
nificantly higher in the surfactant group. Conclusion
of the study revealed that the use of surfactant im-
proved the survival and decreased the associated
morbidities in babies with HMD who required me-
chanical ventilation. The maximum impact was seen
among the babies of 28-33 weeks gestation and birth
weight group 1000-1249 grams. It has been shown that
a single dose of surfactant at birth followed by con-
tinuous positive airway pressure (CPAP) significantly
reduces the subsequent need for mechanical ventila-
tion. Hence, it may be worth considering prophylac-
tic surfactant therapy in high-risk neonates between
28-32 weeks gestation even in the absence of elabo-
rate level III care setup in the country.10
Surfactant preparations
The exogenous surfactant preparations available
currently are natural bovine lung extracts, surfactants
obtained from the lavage of calf lungs, extracts of
porcine lung surfactants, and synthetic preparations.
Administration of exogenous surfactant is con-
sidered an appropriate prophylactic treatment for pre-
mature infants who are at risk of developing RDS.
Those less than 32 weeks gestational age and/or of
birth weights less than 1.25 kg. Early administration
may help to minimize lung injury, which could other-
wise be the result of ventilating surfactant-deficient
lungs. The instillation of exogenous surfactant into
lungs that are still absorbing fetal lung fluid may re-
sult in improved distribution.3
Instillation of surfactant
The most common method used for administering
exogenous surfactant is direct instillation into the
endotracheal tube. This method results in a rapid
spread of material, allowing it to be distributed to the
lung periphery. Other methods of investigated
administrations include aerosolization of the
surfactant as well as instillation in combination with
techniques such as jet ventilation and partial liquid
ventilation.3
General information on the dosage for various
surfactant replacement products is shown on Table 1.
Clinical Trials
Investigations of various exogenous lung surfactant
preparations that are presently available have
demonstrated differences in the improvement of gas
exchange and other pulmonary variables. However, they
have failed to show a statistically significant reduction
in mortality or increased survival without
bronchopulmonary dysplasia (BPD).3 There does
appear to be some indication that the presently available
natural surfactants may be more efficacious than
synthetic preparations when administered to premature
infants. It is also important to note that differences do
exist among the natural surfactants; therefore the
individual characteristics of each must be considered.3
Product
Calfactant
Beractant
Colfosceril
Porcine
Dosage
3 mL/kg of birth weight given in two
aliquots
4 mL/kg of birth weight given in
quarter doses
5 mL/kg of birth weight given over a
4-minute period
2.5 mL/kg of birth weight given in two
aliquots
Additional Doses
May be repeated every 12 hours for up to three
subsequent doses at 12-hour intervals, if indicated
May be repeated after at least 6 hours, up to a total
of four doses within 48 hours of birth
May be repeated after 12 hours and 24 hours, if
indicated
Two subsequent 1.25-mL/kg doses given at 12-
hour intervals, if indicated
TABLE 1. DOSAGE RECOMMENDATIONS FOR COMMONLY USED EXOGENOUS SURFACTANTS3
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Adverse effects of surfactant
One of the undesirable effects that may arise due to
surfactant therapy is transient airway obstruction
(correlated with transient hypoxemia and hypotension).
Changes in cerebral perfusion may also occur in very
premature babies owing to the rapid redistribution of
pulmonary blood flow into cerebral circulation. Rales
and moist sounds may occur transiently, however these
are normal findings. Other effects are transient
bradycardia (11.9%) during multiple dose trials, oxygen
desaturation (9.3%), reflux, pallor, vasoconstriction,
hypotension, hypertension, tube blockage, hypo/
hypercarbia, and apnea.
All effects may be resolved simply by stopping the
treatment or increasing oxygenation and ventilation.4,11
Procedural and physiologic concerns
Points to be considered when employing surfactant
therapy:3,10
1. Endotracheal tube occlusion, bradycardia secondary
to hypoxia, and hemoglobin desaturation due to the
procedures, is suggested to give sedatives.
2. Close monitoring by qualified personnel is
necessary in order to minimize the impact of
complications.
3. Physiologic complications include apnea, the
development of mucous plug, and pulmonary
hemorrhage. Frequently, an immediate improvement
in lung compliance occurs, resulting in an increase of
expiratory tidal volume. Observation of increased
chest expansion should be done. Failure to make
ventilator adjustments in response to improved lung
compliance has results in barotrauma, as well as
volutrauma.
4. Sepsis is the most common complication in
ventilated babies, incidence as high as 67% has
been reported.
5. The increased incidence of PDA in babies who did
not receive surfactant could be explained based
on the known association of PDA and septicemia
in the premature neonates.
Implications for practice
Some studies indicate that infants with RDS treated
with early surfactant replacement therapy and nasal
continuous positive airway pressure (NCPAP) are less
likely to require mechanical ventilation than those
treated with NCPAP and later surfactant therapy.
Current evidence is insufficient to rely on evaluating
the effect of BPD or chronic lung disease (CLD). The
amount of evidence should increase markedly when
several concluded trials of such therapy are reported.12
Surfactant therapy in developing countries
Although it is still expensive, the use and availability
of surfactant has increased globally, including Indonesia.
In fact, there is still dilemma since several countries
still face primary health care problems; on the other
hand, there is a demand and need from certain levels
or segments of the population which require surfactant
treatment. Some factors should be considered in terms
of surfactant use in developing countries.
The cost of surfactant is still high and variable
($800-1000/vial), which is high for developed coun-
tries. This may indeed be twice per capita income in
some countries (Indian per capita $350/year). Thus it
is the least cost effective. The aspect has been well
studied in some countries where a development of
policy for selective and restrictive use has been pro-
posed. Similarly, other developing countries should
develop such strategies. Alternately pharmaceutical
industries should make efforts to produce low cost sur-
factant. In Indonesia, the price is around Rp
4,000,000,- (four million rupiahs), it is equivalent to
US$37-40 per vial and no local product is available.6
Surfactant use presupposes the availability of
trained personnel to manage neonatal ventilation and
facilities to provide total intensive care. This in itself
is a major undertaking. To establish a denovo, a NICU
bed may cost $50,000 in equipment alone. The space,
utilization, availability of personnel (nursing, techni-
cians), etc. will add up to the cost. In developed coun-
tries per diem cost of such operation exceeds $1500/
NICU bed; obviously high tech care is highly expen-
sive. One should be fully aware of such cost analysis
prior to introducing NICU in hospitals. The best al-
ternative is to develop preventive strategies (improved
prenatal care, antenatal steroids) and development
of a regionalized system to pool resources and develop
policies for treatment.6
Besides the existing benefits from surfactant
therapy, there are also increasing complications to be
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considered, such as infections, lack of nutritional sup-
port, and intra-ventricular hemorrhage (IVH). These
complications were attributed to lack of skilled per-
sonnel, or capabilities to minimize infections or im-
prove nutritional support of extremely small weight
infants who survived longer periods of time after sur-
factant therapy. These observations indicate that sur-
factant therapy alone without proper supporting mea-
sures will increase the burden of the disease and prove
to be less cost effective.6
In view of some observations, one might consider
treating infants with surfactant either by aerosol (which
will still require intubation) or use of single intubation
for surfactant instillation followed by NCPAP. Studies
of aerosol treatment of surfactants are in progress but
not yet available for clinical use. Single intubation for
surfactant treatment followed by CPAP has been re-
ported by a few investigators. There is a limited use
specifically in larger infants. The need for superb nurs-
ing care of these infants must be clearly recognized.6
Recommendations of Canadian Pediatrics
Society
The recommendations of Canadian Pediatrics Society
(Table 2) may have come from a developed country;
however, it is important to consider surfactant therapy
as a general and universal recommendation, including
in Indonesia. Further research into retreatment criteria
and optimal timing of prophylactic therapy is required.
TABLE 3. GRADE OF RECOMMENDATION REGARDING THE LEVEL OF EVIDENCE ACCORDING TO THE
CANADIAN PEDIATRICS SOCIETY
Recommendation
Mothers at risk of delivering babies with less than 34 weeks gestation should be given antenatal
steroids
Mothers with threatened delivery before 32 weeks gestation should be transferred to a tertiary centre
if at all possible
Exogenous Surfactant therapy should be given to:
• Intubated infants with RDS
• Intubated infants with meconium aspiration syndrome requiring more than 50% oxygen
• Sick newborn infants with pneumonia and an oxygenation index greater than 15
• Intubated newborn infants with pulmonary hemorrhage which leads to clinical deterioration
• Intubated infants with RDS before transport
• Infants who deliver at less than 29 weeks gestation outside of a tertiary centre should be
considered for immediate intubation followed by surfactant administration after stabilization, if
competent personnel are available
Natural surfactants should be used in:
• Preference to any artificial surfactants available at the time of  publication of this statement
• Infants who are at a significant risk for RDS should receive as soon as they are stable within a
few minutes after intubation
Repeated dose or re-treatment should be given to:
• Infants with RDS who have persistent or recurrent oxygen and ventilatory requirements within
the first 72 hours. Administering more than three doses has not been shown to have any
benefit
• Infant with persistent or recurrent oxygen requirement of 30% more and may be given as early
as 2 hours after the initial dose or, more commonly, 4 to 6 hours after the initial dose
Options for ventilator management that are to be considered after prophylactic surfactant therapy
include very rapid weaning and extubation to CPAP within 1 hour
Centers administering surfactant to newborn infants must ensure the continuous on-site availability
of competent and licensed personnel to deal with acute complications of assisted ventilation and
surfactant therapy
Grade
A
B
A
A
C
C
C
A
A
A
A
A
B
D
Grade A = Consistent level 1 studies
Grade B = Consistent level 2 or 3 studies
Grade C = Level 4 studies
Grade D = Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
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Conclusions
Since level 3 neonatal services or NICU are being
developed in several centers or hospitals around the
country, therefore the knowledge and expertise
regarding surfactant should also be trained to qualified
personnel. Data concerning the use of surfactant
among hospitals in Indonesia varies from never, very
rare, rare and often such data could not yet be
represented.
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